Toronto Memory Program

03/12/2026

On March 26, neurologist Dr. Sharon Cohen of Toronto Memory Program joins BrightFocus Foundation to walk through the early signs of Alzheimer's disease, the conditions that can look like dementia but aren't, and how to have a productive conversation with your doctor.

Register to join live: BrightFocus.org/ZoomInAlz

Register to join live: BrightFocus.org/ZoomInAlz

03/11/2026

Interested in exploring and learning more about Alzheimer’s disease research opportunities for yourself or a loved one? 🧠

A Clinical Trial Educator would be happy to speak with you and answer your questions.

Fill out our contact form today to get started.

03/03/2026

Research has shown that it’s important to get all three types of exercise: aerobic, muscle-strengthening, and balance. Adults should do muscle-strengthening activities at least two days a week and at least 150 minutes (2 1/2 hours) a week of moderate-intensity aerobic exercise. In addition, older adults benefit from balance exercises and doing a combination of all three types of activity.

02/24/2026

This week, the Canadian Drug Expert Committee issued a draft recommendation against public reimbursement of lecanemab (Leqembi) for patients with mild cognitive impairment or mild dementia due to early Alzheimer’s disease.

In a recent interview, our Medical Director, Dr. Sharon Cohen, discusses the clinical trial data, cost considerations, and what this recommendation could mean for patients and families.

Watch the full report here:

The Canadian Drug Expert Committee (CDEC) this week recommended that lecanemab, commonly referred to as Leqembi, should not be reimbursed for the treatment o...

02/12/2026

The TRAVELLER study seeks to identify people who are best suited to participate in one of Roche’s Alzheimer’s disease clinical studies. This study also aims to engage with diverse communities to ensure we include all people living with Alzheimer’s disease.

02/06/2026

A Night of Celebration & Progress!

We were proud to join Sentrex in celebrating the grand opening of their new North York PerCuro Infusion Centre. The centre was specifically designed to provide infusions for individuals with Alzheimer’s disease.

This special evening brought together healthcare professionals, community partners, representatives from the Alzheimer Society of Toronto and other organizations, patients, and staff.

The event celebrated a major milestone: the approval of Canada’s first disease-slowing therapy for Alzheimer’s disease, lecanemab, and the opening of a new onsite infusion centre within our shared building—expanding access for patients to receive treatment in a familiar, supportive setting.

We’re excited to share that patients have already started receiving treatment, making this moment even more impactful. The ribbon cutting was especially meaningful as we celebrated alongside a participant in the pivotal clinical trial that showed the efficacy of lecanemab in slowing disease progression.

Thank you to Percuro and Sentrex for their collaboration and shared commitment to advancing patient-centred care.

An unforgettable night—and an exciting step forward for our community.

02/03/2026

Do You Want To Make A Difference In Alzheimer’s Research?

The Bio-Hermes-002 research study seeks volunteers with or without memory concerns to help identify blood or digital tests that could help predict the presence of amyloid plaques or tau tangles in the brain, which are the hallmarks of Alzheimer’s disease.

To learn more: https://globalalzplatform.org/biohermes-002study/

01/26/2026

We’re proud to share an important milestone in Alzheimer’s disease care in Canada.

Last week, Toronto Memory Program, in partnership with PerCuro by Sentrex, supported one of the first infusions of a newly approved treatment in the country.

This moment marks the introduction of Canada’s first disease-slowing therapy for Alzheimer’s disease, opening a new chapter in care for patients and their families.

01/15/2026

Dr. Kore Kai Liow, Neurologist and Researcher at the Hawaii Memory Disorders Center and Alzheimer’s Research Unit, speaks about an ongoing Roche-sponsored clinical trial studying trontinemab in people with early symptomatic Alzheimer’s disease. The discussion highlights how this investigational therapy uses Roche’s Brainshuttle technology to improve delivery of anti-amyloid antibodies across the blood–brain barrier, with the goal of achieving more effective amyloid clearance in the brain. Watch to learn more about the science behind trontinemab and the importance of clinical research in advancing Alzheimer’s disease treatment and care.

Kore Kai Liow, MD, Neurologist and Reseacher at Hawaii Memory Disorders Center and Alzheimer's Research Unit, Honolulu explained to Sara Mattison, News Anch...

12/30/2025

Trontinemab is one of the latest disease-modifying drugs currently being tested in late-stage clinical trials. Here’s what we know about this potential new treatment for Alzheimer's disease.

12/18/2025

🎄 Holiday Hours at Toronto Memory Program 🎄

Please note that TMP will be closed on Christmas Day, Boxing Day, and New Year’s Day.

We wish you and your loved ones a wonderful holiday season filled with warmth, health, and joy. 💫

12/04/2025

Making healthy choices can help you avoid many chronic diseases and can even lower your risk of severe illness from some infectious diseases, such as the flu and COVID-19. But healthy behaviors are only part of the picture. Getting routine preventive care can help you stay well and catch problems early.

Knowing your family health history can help you stay well and catch problems early.